Who is sponsoring NCT05257954?

NCT05257954 is sponsored by Josep Rodes-Cabau.

What condition does NCT05257954 study?

NCT05257954 studies Transcatheter Left Atrial Appendage Closure, Frailty.

Is NCT05257954 still recruiting?

NCT05257954 is currently recruiting now. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT05257954: Frail-LAAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Frailty in Patient Undergoing Percutaneous Left Atrial Appendage Closure.

Recruiting now Last updated 24 March 2026

What this trial tests

trial in Transcatheter Left Atrial Appendage Closure in 500 participants. Currently enrolling.

Timeline

1 March 2022

Primary endpoint
1 March 2027

1 March 2029

Quick facts

Lead sponsor	Josep Rodes-Cabau
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 March 2022
Primary completion	1 March 2027
Estimated completion	1 March 2029
Sites	1 location across Canada

Conditions studied

Transcatheter Left Atrial Appendage Closure — all drugs for Transcatheter Left Atrial Appendage Closure →
Frailty — all drugs for Frailty →

Sponsor

Josep Rodes-Cabau

Who can join

18 and older, any sex, with Transcatheter Left Atrial Appendage Closure or Frailty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the prevalence and severity of frailty in patients undergoing LAAC, as well as its association to peri-procedural and long-term outcomes and quality of life.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Epicardial Ligation of the Left Atrial Appendage in Octogenarians: Safety and Long-Term Efficacy.
Nentwich K, Kazaishvilli N, Sauer E, Berkovitz A, et al · · 2025 · cited 1× · PMID 40142596 · DOI 10.3390/jcm14061787

Verify or expand the search:

Other Josep Rodes-Cabau trials

Trials by the same sponsor.

NCT05907694 — Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure · NA · recruiting
NCT04475510 — Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic St · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05257954 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Josep Rodes-Cabau
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05257954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing